You have no items in your shopping cart.
Product Details
| Alternate Name | ZD-1839 |
|---|---|
| Appearance | White to off-white solid |
| CAS # | 184475-35-2 |
| Molecular Formula | C₂₂H₂₄ClFN₄O₃ |
| Molecular Weight | 446.9 |
| Purity | ≥99% by HPLC |
| Solubility | DMSO (100 mg/ml) |
| SMILES | COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4 |
| InChi | InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27) |
| InChi Key | XGALLCVXEZPNRQ-UHFFFAOYSA-N |
| PubChem CID | 123631 |
| MDL Number | MFCD04307832 |
| Handling | Protect from light and moisture |
| Storage Conditions | -20°C |
| Shipping Conditions | RT |
| USAGE | For Research Use Only! Not For Use in Humans. |
Details
Gefitinib was found to be a potent inhibitor of EGFR kinase (Ki = 0.40 nM), but much weaker against ErbB-2 kinase (Ki = 870 nM) and ErbB-4 kinase (Ki = 1.1 µM). The IC₅₀ values for Gefitinib to inhibit HT-29 and LoVo cell growth were 23.6 - >100 µM and 7.3 - 48.5 µM, respectively, when the exposure times are from 18 hours to 3 days. The IC₅₀ values of Gefitinib to the breast cancer cell lines BT20, HCC1937, MDA-MB-231, BT474, and SKBR3 are 15.5±1.4, 8.4±1.5, 20.7±1.1, 0.25±0.05, 0.88±0.31 µM, respectively
Why buy BioVision Products?
 |
 |
 |
 |
Innovation |
Affordability |
Global Presence |
Technical Support |
BioVision aims to provide our customers innovative tools for accelerating drug discovery and biological research. BioVision offers >8,000 products including the most comprehensive array of assay kits for key targets in Metabolic pathways. |
BioVision is committed to providing the highest quality products at a competitive price. |
We have a broad network of global distributors who are ready to address your research needs and ensure fast delivery. |
Our highly trained Technical Support team provides comprehensive product support and is dedicated to resolving your issues quickly and efficiently. |
Leong et al., Targeting Cancer Stem Cell Plasticity Through Modulation of Epidermal Growth Factor and Insulin-Like Growth Factor Receptor Signaling in Head and Neck Squamous Cell Cancer. Stem Cells Trans Med, Sep 2014; 3: 1055 - 1065.
For more citations of this product click here
